Bhattacharya Deepta, Bryder David, Rossi Derrick J, Weissman Irving L
Institute of Cancer and Stem Cell Biology and Medicine, Department of Pathology, Stanford University School of Medicine, Stanford, California, USA.
Cell Cycle. 2006 Jun;5(11):1135-9. doi: 10.4161/cc.5.11.2772. Epub 2006 Jun 1.
The replacement of abnormal hematopoietic stem cells (HSCs) with normal transplanted HSCs can correct a wide range of hematologic disorders. Here, we provide evidence that transplantation of more differentiated progenitor cells can be used to more rapidly correct lymphoid deficiencies in unconditioned immunocompromised mice. Transplantation of flk2+ multipotent progenitors led to robust B and T cell reconstitution that was maintained for at least 16 weeks. Antigenic challenge at 16 weeks post-transplantation revealed that reconstituted lymphocytes maintained a functional repertoire. In contrast to the persistent lymphocytic engraftment, myeloid chimerism was lost by 12 weeks post-transplantation consistent with the fact that flk2+ progenitors are non-self-renewing. Thus, while more differentiated progenitors are capable of rescuing lymphoid deficiencies, transplantation of HSCs must be used for the correction of non-lymphoid disorders, and, we propose, very long-term immune reconstitution. Based on recent evidence, we discuss novel strategies to achieve the replacement of abnormal HSCs without the use of cytotoxic conditioning regimens.
用正常移植的造血干细胞(HSCs)替代异常造血干细胞可以纠正多种血液系统疾病。在此,我们提供证据表明,移植分化程度更高的祖细胞可用于更快速地纠正未预处理的免疫受损小鼠的淋巴细胞缺陷。flk2 +多能祖细胞的移植导致强大的B细胞和T细胞重建,这种重建至少维持了16周。移植后16周的抗原刺激表明,重建的淋巴细胞保持了功能性库。与持续的淋巴细胞植入相反,移植后12周髓系嵌合体消失,这与flk2 +祖细胞不能自我更新的事实一致。因此,虽然分化程度更高的祖细胞能够挽救淋巴细胞缺陷,但必须使用造血干细胞移植来纠正非淋巴细胞疾病,并且,我们认为,用于非常长期的免疫重建。基于最近的证据,我们讨论了在不使用细胞毒性预处理方案的情况下实现异常造血干细胞替代的新策略。